Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ATOS with free AI briefings, catalyst countdowns, and dilution alerts.

ATOS · Atossa Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$20.6M Cash on Hand
8.1mo Cash Runway
5.3% Short Interest
$19 Analyst Target (3)
Follow ATOS by email Get an email when ATOS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ATOS, unsubscribe in one click. Privacy

📣 What ATOS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Endoxifen Breast Neoplasms Phase 2 · NCT05607004 Active not recruiting
Topical endoxifen Mammographic Breast Density Phase 2 · NCT04616430 Completed
Z-Endoxifen Breast Density Phase 2 · NCT05068388 Completed
AT-301A Healthy Phase 1 · NCT04519788 Completed
AT-301B Healthy Phase 1 · NCT04519788 Completed

Also used in these trials (approved or third-party drugs, not ATOS's own candidates): Fulvestrant, Goserelin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ATOS holds $20.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.6M/quarter from operations, an estimated runway of 8.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ATOS files for a raise →

👥 Who Owns ATOS

Insiders 2.2% Institutions 18.2% Public and other holders 79.6%
HolderTypeShares% of sharesAs of
Vanguard Capital Management LLC Institution (13F) 723,494 7.25% 2026-09-30
Blackrock Inc. Institution (13F) 337,242 3.38% 2026-09-30
Renaissance Technologies, LLC Institution (13F) 219,814 2.20% 2026-09-30
Geode Capital Management, LLC Institution (13F) 191,154 1.92% 2026-09-30
Vanguard Fiduciary Trust Co Institution (13F) 105,166 1.05% 2026-09-30
Steven C Quay
President & CEO, Director · +3.16M options
Insider 89,521 0.90% 2026-03-27
State Street Corporation Institution (13F) 79,522 0.80% 2026-09-30
Mark James Daniel
Chief Financial Officer · +578,000 options
Insider 63,000 0.63% 2026-03-26
UBS Group AG Institution (13F) 61,016 0.61% 2026-09-30
Ameriprise Financial, Inc. Institution (13F) 54,824 0.55% 2026-09-30
Susquehanna International Group, LLP Institution (13F) 43,026 0.43% 2026-09-30
Jonathan Finn
Director · +375,000 options
Insider 11,666 0.12% 2026-05-12

Share count 9,979,298 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-05-12
filed 2026-05-14
Chen Shu-Chih
Award (A) 10,000 – 10,000
2026-05-12
filed 2026-05-14
Remmel H. Lawrence
Award (A) 10,000 – 10,683
2026-05-12
filed 2026-05-14
Finn Jonathan
Award (A) 10,000 – 11,666
2026-05-12
filed 2026-05-14
Galli Stephen J
Award (A) 10,000 – 10,006
2026-05-12
filed 2026-05-14
Cigler Tessa
Award (A) 10,000 – 10,000

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ATOS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ATOS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.